A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease

Bibliography

• Allain H, Schuck S, Mauduit N. Depression in Parkinson's disease. BMJ 2000;320:1287-8
   PubMed Web of Science ®Google Scholar
• Slaughter JR, Slaughter KA, Nichols D, Prevalence, clinical manifestations, etiology and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:187-96
   PubMed Web of Science ®Google Scholar
• Reijnders JS, Ehrt U, Weber WE, A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23(2):183-9
   PubMed Web of Science ®Google Scholar
• Lieberman A. Depression in Parkinson's disease – a review. Acta Neurol Scand 2006;113(1):1-8
   PubMed Web of Science ®Google Scholar
• Kuopio AM, Marttila RJ, Helenius H, The quality of life in Parkinson's disease. Mov Disord 2000;15:216-23
   PubMed Web of Science ®Google Scholar
• Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-12
   PubMed Web of Science ®Google Scholar
• Halliday GM, Li YW, Blumbergs PC, Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990;27:373-85
   PubMed Web of Science ®Google Scholar
• Tom T, Cummings JL. Depression in Parkinson's disease. Pharmacological characteristics and treatment. Drugs Aging 1998;12:55-74
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S, Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(6):573-80
   PubMed Web of Science ®Google Scholar
• Vajda FJ, Solinas C. Current approaches to management of depression in Parkinson's disease. J Clin Neurosci 2005;12(7):739-43
   PubMedGoogle Scholar
• Gerber PD, Lynd LD. Selective serotonin reuptake inhibitor- induced movement disorders. Ann Pharmacother 1998;32:692-8
   PubMed Web of Science ®Google Scholar
• Richard IH, McDermott MP, Kurlan R, A randomized, double blind, placebo-controlled trial of antidepressant in Parkinson disease. Neurology 2012;78:1229-36
   PubMed Web of Science ®Google Scholar
• Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005;27(8):1126-43
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63(4):308-15
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36(6):383-90
   PubMed Web of Science ®Google Scholar
• Girardi P, Pompili M, Innamorati M, Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol 2009;24(3):177-90
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Schatzberg AF, Goldstein DJ, Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36(4):106-32
   PubMedGoogle Scholar
• Mancini M, Gianni W, Rossi A, Amore M. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data. Expert Opin Pharmacother 2009;10(5):847-60
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton R. Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease. Volume 2 Macmillan; Florham Park, NJ: 1987. p. 153-63
   Google Scholar
• DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86(1):102-6
   PubMed Web of Science ®Google Scholar
• Brannan SK, Mallinckrodt CH, Brown EB, Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39(1):43-53
   PubMed Web of Science ®Google Scholar
• Ravina B, Camicioli R, Como PG, The impact of depressive symptoms in early Parkinson disease. Neurology 2007;69(4):342-7
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Nuti A, Piccinni A, Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000;55(8):1216-18
   PubMed Web of Science ®Google Scholar
• Dell'Agnello G, Ceravolo R, Nuti A, SSRIs do not worsen Parkinson's disease: evidence from an open label prospective study. Clin Neuropharmacol 2001;24(4):221-7
   PubMed Web of Science ®Google Scholar
• Weintraub D, Morales KH, Moberg PJ, Antidepressant studies in Parkinson disease: a review and metaanalysis. Mov Disord 2005;20(9):1161-9
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci 2010;289(1-2):74-80
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Shannon K, Voon V, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66(7):996-1002
   PubMed Web of Science ®Google Scholar
• Gomez-Esteban JC, Tijero B, Somme J, Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease. J Neurol 2011;258(3):494-9
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H, Bienfait K. Sleep disturbances in Parkinson's disease. Mov Disord 2010;25(Suppl 1):S117-22
   PubMed Web of Science ®Google Scholar
• Marinus J, Visser M, van Hilten JJ, Assessment of sleep and sleepiness in Parkinson's disease. Sleep 2003;26(8):1049-54
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Pal S, Di Marco A, The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:629-35
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Prakash A, Andorn AC, Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006;40(4):337-48
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63(3):225-31
   PubMed Web of Science ®Google Scholar
• Whitmyer VG, Dunner DL, Kornstein SG, A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiaty 2007;68(12):1921-30
   PubMed Web of Science ®Google Scholar
• Dunner DL, Wohlreich MM, Mallinckrodt CH, Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg QD starting doses. Curr Ther Res 2005;66(6):522-40
   PubMedGoogle Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology, revised. US Dept. of Health, Education and Welfare; Bethesda (MD): 1976
   Google Scholar
• Beck AT, Ward CH, Mendelson M, An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71
   PubMed Web of Science ®Google Scholar
• Peto V, Jenkinson C, Fitzpatrick R, The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995;4:241-8
   PubMed Web of Science ®Google Scholar